Remove tag pharma-sales
article thumbnail

The current pharma business model is unsustainable

World of DTC Marketing

In pharma, growth depends on new products with hefty price tags when over 80% of voters want lower costs for their prescription drugs. Biogen’s failure should be a warning to other pharma companies. It should be a warning to other pharma companies. Now Biogen is a shell of a company selling off assets to survive.

Pharma 210
article thumbnail

Turnover in Pharma: Revealing the Price Tag

Revosuite

When a medical representative leaves the company he doesn't only take institutional knowledge with him, but his retinotopic intelligence, customer relationships, sales territory intelligence that he has built while working there. The post Turnover in Pharma: Revealing the Price Tag appeared first on REVO.

Pharma 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

What Tech Trends Do Life Sciences Marketers Need to Know About?

PM360

Derek Choy The Fine-Tuning API (Application Programming Interface) in OpenAI now enables the creation of hyper-personalized content to support brand managers, customer experience professionals, sales teams, and medical science liaisons. Another capability made possible by fine-tuning is the enhancement of content tagging.

article thumbnail

The FDA and Aduhelm: WTF?

World of DTC Marketing

Source: Fierce Pharma If that enthusiasm pans out in the long run, it could mean at least 300,000 patients taking the drug, or $10 billion to $15 billion in peak Aduhelm from U.S. sales alone, which is above consensus estimates of around $7 billion to $8 billion, the team said. Not to mention the $56,000 annual price tag.

FDA 218
article thumbnail

Axsome bounces back as FDA clears depression drug

pharmaphorum

There’s no word yet on its pricing, but for comparison Spravato was launched with an annual price tag of around $32,400, which the Institute for Clinical and Economic Review (ICER) concluded was around 25% to 52% too high to be cost effective.

FDA 83
article thumbnail

J&J builds case for antidepressant Spravato with head-to-head trial

pharmaphorum

Despite J&J’s high hopes for the drug, sales have remained low, not warranting a mention in any of J&J’s quarterly financial updates since launch, and the company will look to the new data to try to encourage take-up. and 17.6%, respectively, according to J&J’s pharma unit Janssen. and 14.1%, respectively.

Sales 52
article thumbnail

CNPR Certification Reviews - Cracking the Code to Pharmaceutical Sales Success

Contrarian Sales Techniques

Craving a career in the lucrative world of pharmaceutical sales? Well, I've been there, navigated the CNPR maze myself, and emerged (hopefully) the other side a certified, career-ready pharma pro. They'll credit the program's real-world simulations and role-playing scenarios for honing their sales skills and ethical compass.